Market Place
Sourcing Support
Proqr Nominates Dr. Lykke Hinsch Gylvin To Board
30 Apr 2026 //
GLOBENEWSWIRE
Proqr To Webcast Presentation At 2026 Citizens Life Sciences Conf
03 Mar 2026 //
GLOBENEWSWIRE
Proqr Announces Planned Changes To Board Composition
09 Feb 2026 //
GLOBENEWSWIRE
Proqr To Participate In 8Th Annual Evercore Healthcare Conference
01 Dec 2025 //
GLOBENEWSWIRE
ProQR Announces Second Quarter 2025 Operating & Financial Result
07 Aug 2025 //
GLOBENEWSWIRE
ProQR Announces Year End 2024 Operating and Financial Results
13 Mar 2025 //
GLOBENEWSWIRE
ProQR To Present On Axiomer™ RNA Editing At RNA Summit
18 Jun 2024 //
GLOBENEWSWIRE
ProQR Announces First Quarter 2024 Operating and Financial Results
09 May 2024 //
GLOBENEWSWIRE
ProQR Nominates Maier to Board, Announces May 22 Shareholder Meeting
23 Apr 2024 //
GLOBENEWSWIRE
ProQR Highlighting Axiomer RNA Editing At ASGCT 2024
22 Apr 2024 //
GLOBENEWSWIRE
ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio
19 Apr 2024 //
GLOBENEWSWIRE
ProQR Announces Year End 2023 Operating and Financial Results
13 Mar 2024 //
GLOBENEWSWIRE
ProQR Highlights New Platform Data from Presentation on Axiomer Technology
19 Jan 2024 //
GLOBENEWSWIRE
ProQR and Rett Syndrome Research Trust Join Forces with Axiomer Collaboration
05 Jan 2024 //
GLOBENEWSWIRE
ProQR Announces Third Quarter 2023 Operating and Financial Results
07 Nov 2023 //
GLOBENEWSWIRE
ProQR Strengthens Intellectual Property Estate for ADAR-mediated RNA Editing
06 Nov 2023 //
GLOBENEWSWIRE
ProQR Announces Participation in Chardan 7th Annual Genetic Medicines Conference
28 Sep 2023 //
GLOBENEWSWIRE
ProQR Therapeutics Provides Update on Ophthalmic Assets
27 Sep 2023 //
GLOBENEWSWIRE
ProQR Announces Webcast at HC Wainwright 25th Annual Investment Conference
07 Sep 2023 //
GLOBENEWSWIRE
ProQR Announces Second Quarter 2023 Operating and Financial Results
03 Aug 2023 //
GLOBENEWSWIRE
ProQR has inked a deal with French company Laboratoires Théa
01 Aug 2023 //
ENDPTS
ProQR finds eye disease partner in Europe, hands off two late-stage candidates
01 Aug 2023 //
ENDPTS
ProQR offloads 2 eye disease assets to Théa for $14M upfront
01 Aug 2023 //
FIERCE BIOTECH
ProQR to Present Data on its Axiomer® RNA Editing Technology RNA Editing Summit
06 Jul 2023 //
GLOBENEWSWIRE
ProQR Announces First Quarter 2023 Operating and Financial Results
16 May 2023 //
GLOBENEWSWIRE
ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023
09 May 2023 //
GLOBENEWSWIRE
ProQR Announces Upcoming Investor Conferences in April and May
20 Apr 2023 //
GLOBENEWSWIRE
ProQR Announces Annual Meeting of Shareholders to be Held May 17, 2023
18 Apr 2023 //
GLOBENEWSWIRE
ProQR Announces Pipeline Targets and Highlights Axiomer RNA Editing Platform
29 Mar 2023 //
GLOBENEWSWIRE
ProQR Announces Defense of Axiomer Patent Protecting ADAR-mediated RNA Editing
14 Mar 2023 //
GLOBENEWSWIRE
ProQR to Present at Upcoming Scientific and Industry Conferences
07 Mar 2023 //
GLOBENEWSWIRE
ProQR Therapeutics to Host Virtual R&D Event on March 29, 2023
28 Feb 2023 //
GLOBENEWSWIRE
Lilly pays $75M to widen RNA editing deal with ProQR
23 Dec 2022 //
BIOPHARMADIVE
ProQR Announces Conference Call to Discuss Axiomer® RNA Editing Platform
21 Dec 2022 //
GLOBENEWSWIRE
ProQR to Present its Axiomer® RNA Editing Technology at Oligonucleotide &Peptide
14 Nov 2022 //
GLOBENEWSWIRE
ProQR Announces Webcast of Presentation at the Upcoming Stifel 2022 Conference
03 Nov 2022 //
GLOBENEWSWIRE
Korea establishes novel strategy to tackle Huntington’s disease?
13 Sep 2022 //
BIOSPECTRUMASIA
ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner
11 Aug 2022 //
GLOBENEWSWIRE
ProQR to Participate in the LifeSci 2nd Annual Genetic Medicines Symposium
28 Jun 2022 //
GLOBENEWSWIRE
ProQR Announces Annual General Meeting of Shareholders
01 Jun 2022 //
GLOBENEWSWIRE
ProQR to Present its Axiomer RNA Editing Technology at the TIDES USA 2022
09 May 2022 //
GLOBENEWSWIRE
ProQR to Present at the Retinal Cell and Gene Therapy Innovation Summit
26 Apr 2022 //
GLOBENEWSWIRE
ProQR to Participate in the Kempen Life Sciences Conference
19 Apr 2022 //
GLOBENEWSWIRE
ProQR to lay off 30% of staff following eye drug setback
14 Apr 2022 //
BIOPHARMADIVE
ProQR Announces Additional Sepofarsen Illuminate Trial Analyses
13 Apr 2022 //
GLOBENEWSWIRE
ProQR to Present Axiomer RNA Editing Platform Technology at RNA Editing Summit
04 Apr 2022 //
GLOBENEWSWIRE
ProQR to Participate in the Cantor Virtual Rare Orphan Disease Summit
23 Mar 2022 //
GLOBENEWSWIRE
ProQR Appoints John Maraganore, PhD, as Strategic Advisor
07 Mar 2022 //
GLOBENEWSWIRE
ProQR Announces Q4 and Full Year 2021 Operating and Financial Results
24 Feb 2022 //
GLOBENEWSWIRE
ProQR eye drug comes up short in key study, surprising company and investors
12 Feb 2022 //
BIOPHARMADIVE
ProQR Shows Results from Phase 2/3 Illuminate Trial of Sepofarsen
11 Feb 2022 //
GLOBENEWSWIRE
ProQR to Present at Upcoming SVB Leerink Conference
07 Feb 2022 //
GLOBENEWSWIRE
ProQR: Last Patient Completes 12 Month Visit in Phase 2/3 Trial of Sepofarsen
04 Jan 2022 //
GLOBENEWSWIRE
ProQR Announces Amendment to Convertible Debt Agreement with Pontifax
30 Dec 2021 //
GLOBENEWSWIRE
RNA Editor ProQR Lines Up $1.5 Billion Deal with Eli Lilly
09 Sep 2021 //
BIOSPACE
Eli Lilly follows up MiNA pact with a 2nd $1B-plus RNA collab, this time with ProQR
09 Sep 2021 //
FIERCEBIOTECH
ProQR Announces Virtual Presentation at EURETINA 2021
06 Sep 2021 //
FIRSTWORD PHARMA
ProQR Announces Second Quarter 2021 Operating and Financial Results
05 Aug 2021 //
GLOBENEWSWIRE
ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Extension
23 Apr 2021 //
EYEWIRE
